Business
Cytophage Technologies Ltd. Secures Government of Canada New Substance Notification Approval to Facilitate Enterococcus Phage Therapy Trials
(TheNewswire) Government of Canada Approval of Human Therapeutic Phage Enables a Critical F...
About this update from Cytophage Technologies Ltd.
[{"type":"text","content":"Cytophage Technologies Ltd. Secures Government of Canada New Substance Notification Approval to Facilitate Enterococcus Phage Therapy Trials\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Government of Canada Approval of\nHuman Therapeutic Phage Enables a Critical First Step Towards Clinical\nDeployment and Creates Pathway to Multi-Phage Commercial\nProduct\n \n\n\n\n Winnipeg, May 8, 2025\n \n\n —\n \n\n TheNewswire -\n \n\n Cytophage Technologies Ltd. (“Cytophage” or the\n“Company”) (TSXV: CYTO, FSE: 70G), a biotechnology company\nadvancing precision bacteriophage therapeutics, announced today that\nit has received Government of Canada approval under the New Substance\nNotification (NSN) framework for its novel phage candidate targeting\n \n\n Enterococci\n \n\n for prosthetic joint infections (PJIs). This\n \n\n initial\n \n\n regulatory milestone is a\nfoundational step in Cytophage’s broader clinical development\nstrategy to create a combination phage treatment capable of addressing\nthe multiple bacterial species commonly involved in PJIs.\n \n\n\n\n Enterococci,\n \n\n particularly\n \n\n E.\nfaecalis\n \n\n and\n \n\n E. faecium\n \n\n , are\namong the most challenging pathogens in orthopedic infections due to\nbiofilm formation and antibiotic resistance (\n \n\n\n\n Journal of Medical\nMicrobiology\n \n\n\n\n\n )\n \n\n\n . Phage therapy offers a\ntargeted, adaptive, and biofilm-disruptive approach to treating such\ninfections, particularly in patients for whom conventional antibiotics\nand surgeries have failed.\n \n\n\n\n “Antibiotics continue to fail at an accelerated rate\nfor chronic bacterial infections such as those in prosthetic joint\ninfections, and the medical field is looking for safe and effective\nalternatives,” commented Dr. Steven Theriault, CEO of Cytophage.\n“This milestone accelerates our path to clinical validation and\nfalls within our long-term commercialization strategy for human\ntherapy. It allows us to move swiftly into patient-specific,\ncompassionate use settings and ultimately scale into Phase 1 trials.\nWe believe this represents a paradigm shift in treating chronic and\npolymicrobial implant-associated infections.”\n \n\n\n\n Clinical Roadmap and Market\nOpportunity\n \n\n\n\n Follow...